Compare ADMA Biologics Inc (ADMA) vs 3M Company (MMM) Price & Performance

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

3M (MMM) trades at $183.58, up 0.85% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding expectations by 6.7%, and raised full-year guidance. Revenue trends show stabilization after 2023 challenges, with 2025 revenue of $24.95B and net income margin of 13.02%. Analyst sentiment is mixed with 48% buy ratings but the stock trades above the consensus price target of $173.

The outlook remains positive with operational improvements and innovation driving growth, particularly in Safety & Industrial and Transportation segments. Key risks include litigation liabilities, macroeconomic headwinds, and valuation concerns with elevated P/E of 32.5. The EBO partnership with Microsoft presents long-term data center growth opportunities, though current pricing may limit near-term upside potential.